Dragon Pharmaceutical Inc.
OTC Bulletin Board : DRUG

Dragon Pharmaceutical Inc.

July 11, 2005 22:41 ET

Dragon Announces Date set for 2005 Annual Stockholder Meeting

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - July 11, 2005) - Dragon Pharmaceutical Inc. (TSX:DDD)(OTCBB:DRUG)(BBSE:DRP) ("the Company") is pleased to announce that August 12, 2005 has been set as the date for the annual stockholder meeting of the Company.

The annual meeting of Dragon stockholders will be held at Dragon's corporate offices at Suite 1900, 1055 West Hastings Street, Vancouver, Canada at 10:00 a.m. Pacific Time. Stockholders of Dragon of record as of the close of business on July 12, 2005 will be entitled to vote on the following 5 proposals at the meeting:

- elect five nominees as members of the Board of Directors to serve until their successors are elected and qualified;

- approve an amendment to our Certificate of Incorporation to eliminate Article VII which states a specified number of directors;

- approve an amendment to Article II, Section 1 of our Bylaws to allow the Board of Directors to set the number of directors at not less than one and not more than eleven directors;

- approve the adoption of the 2005 Stock Option Plan; and

- approve the adjournment of the annual meeting for any permitted reason, including, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the annual meeting to approve the proposals.

On or about July 14, 2005, the Company will send to these stockholders a copy of the definitive proxy statement in connection to the annual meeting.

About Dragon Pharmaceutical Inc.

Incorporated in Florida, USA, Dragon Pharmaceutical Inc. is an international pharmaceutical company headquartered in Vancouver, Canada, with 4 production facilities located in Nanjing and Datong, China. On January 12, 2005, Dragon completed the acquisition of Oriental Wave Holding Limited. As a result of the acquisition, Dragon has transformed itself into a diversified and growth oriented generic pharmaceutical company with three key business units: (1) Pharma division for 44 generic prescription, over-the-counter and sterilized bulk drugs; (2) Chemical division for bulk pharmaceutical chemicals and intermediates (Clavulanic Acid and 7-ACA, Abamectin); and (3) Biotech division for recombinant drugs (EPO and G-CSF). The Company, after the acquisition, has significantly increased the size of operations and now has four manufacturing facilities in China (three in Datong city and one in Nanjing city), approximately 1,800 employees, with over 1,200 sales representatives in China, and approximately 55 key products in 86 different dosages and presentations currently in the market.

This press release contains forward looking statements. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward looking statements. Readers should not place undue reliance on forward looking statements, which only reflect the view of management as of the date hereof. The Company does not undertake the obligation to publicly revise these forward looking statements to reflect subsequent events or circumstances. Readers should carefully review the risk factors and other factors described in its periodic reports with the Securities and Exchange Commission.

Contact Information